Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.

Mol Ther Oncolytics · 2019 · PMC6838941 · PMID 31720371

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

These findings may be significant not only because this is the first report of non-nucleoside types of DOT1L inhibitor with the anti-metastatic activity but also because DOT1L may be a potential target for metastatic breast cancer.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.